147 related articles for article (PubMed ID: 30892690)
1. Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3.
Ballabio S; Craparotta I; Paracchini L; Mannarino L; Corso S; Pezzotta MG; Vescio M; Fruscio R; Romualdi C; Dainese E; Ceppi L; Calura E; Pileggi S; Siravegna G; Pattini L; Martini P; Delle Marchette M; Mangioni C; Ardizzoia A; Pellegrino A; Landoni F; D'Incalci M; Beltrame L; Marchini S
Int J Cancer; 2019 Nov; 145(10):2670-2681. PubMed ID: 30892690
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.
Paracchini L; Beltrame L; Grassi T; Inglesi A; Fruscio R; Landoni F; Ippolito D; Delle Marchette M; Paderno M; Adorni M; Jaconi M; Romualdi C; D'Incalci M; Siravegna G; Marchini S
Clin Cancer Res; 2021 May; 27(9):2549-2559. PubMed ID: 33323403
[TBL] [Abstract][Full Text] [Related]
3. PRKDC-Mediated NHEJ May Play a Crucial Role in Aneuploidy of Chromosome 8-Driven Progression of Ovarian Cancer.
Luan W; Cheng H; Xie H; Liu H; Wang Y; Wang S; Ye X; Zhu H; Tang F; Li Y; Chang X
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732044
[TBL] [Abstract][Full Text] [Related]
4. Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas.
Sonoda G; Palazzo J; du Manoir S; Godwin AK; Feder M; Yakushiji M; Testa JR
Genes Chromosomes Cancer; 1997 Dec; 20(4):320-8. PubMed ID: 9408747
[TBL] [Abstract][Full Text] [Related]
5. Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non-BRCAness high grade ovarian carcinoma.
Goundiam O; Gestraud P; Popova T; De la Motte Rouge T; Fourchotte V; Gentien D; Hupé P; Becette V; Houdayer C; Roman-Roman S; Stern MH; Sastre-Garau X
Int J Cancer; 2015 Oct; 137(8):1890-900. PubMed ID: 25892415
[TBL] [Abstract][Full Text] [Related]
6. Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors.
Kumar M; Bowers RR; Delaney JR
Cell Cycle; 2020 Nov; 19(22):3154-3166. PubMed ID: 33121339
[TBL] [Abstract][Full Text] [Related]
7. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
Sung CO; Song IH; Sohn I
Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
[TBL] [Abstract][Full Text] [Related]
8. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
10. Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.
Pesenti C; Beltrame L; Velle A; Fruscio R; Jaconi M; Borella F; Cribiù FM; Calura E; Venturini LV; Lenoci D; Agostinis F; Katsaros D; Panini N; Bianchi T; Landoni F; Miozzo M; D'Incalci M; Brenton JD; Romualdi C; Marchini S
Eur J Cancer; 2022 Aug; 171():85-95. PubMed ID: 35714451
[TBL] [Abstract][Full Text] [Related]
11. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
[TBL] [Abstract][Full Text] [Related]
12. The chromosome 3q26 OncCassette: A multigenic driver of human cancer.
Fields AP; Justilien V; Murray NR
Adv Biol Regul; 2016 Jan; 60():47-63. PubMed ID: 26754874
[TBL] [Abstract][Full Text] [Related]
13. Chromosome instability region analysis and identification of the driver genes of the epithelial ovarian cancer cell lines A2780 and SKOV3.
Li J; Chen Z; Xiao W; Liang H; Liu Y; Hao W; Zhang Y; Wei F
J Cell Mol Med; 2023 Nov; 27(21):3259-3270. PubMed ID: 37525498
[TBL] [Abstract][Full Text] [Related]
14. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
[TBL] [Abstract][Full Text] [Related]
15. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
[TBL] [Abstract][Full Text] [Related]
16. Genetically predicted circulating protein biomarkers and ovarian cancer risk.
Considine DPC; Jia G; Shu X; Schildkraut JM; Pharoah PDP; Zheng W; Kar SP;
Gynecol Oncol; 2021 Feb; 160(2):506-513. PubMed ID: 33246661
[TBL] [Abstract][Full Text] [Related]
17. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
18. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study.
Calura E; Ciciani M; Sambugaro A; Paracchini L; Benvenuto G; Milite S; Martini P; Beltrame L; Zane F; Fruscio R; Marchette MD; Borella F; Tognon G; Ravaggi A; Katsaros D; Bignotti E; Odicino F; D'Incalci M; Marchini S; Romualdi C
Cells; 2019 Dec; 8(12):. PubMed ID: 31805750
[TBL] [Abstract][Full Text] [Related]
20. High amplification of PVT1 and MYC predict favorable prognosis in early ovarian carcinoma.
Yamamoto A; Kurata M; Yamamoto K; Nogawa D; Inoue M; Ishibashi S; Ikeda M; Miyasaka N; Kitagawa M
Pathol Res Pract; 2020 Nov; 216(11):153175. PubMed ID: 32841774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
